Systemic Teriparatide Administration Promotes Osseous Regeneration of an Intrabony Defect: A Case Report.

ABSTRACT:

Introduction

Teriparatide comprises the first 34 amino acids of parathyroid hormone and is a systemic anabolic agent that is Food and Drug Administration approved for the treatment of osteoporosis but not for periodontitis. To our knowledge, this is the first clinical case report to document the treatment of a patient with severe periodontitis using an open-flap debridement procedure in conjunction with teriparatide.

Case presentation

A 45-year-old female patient was diagnosed with severe chronic periodontitis, including the presence of an intrabony defect on tooth #6. She received open-flap debridement surgery in conjunction with daily systemic administration of 20 μg teriparatide, oral vitamin D, and calcium supplements for 6 weeks. Radiographic, clinical, gingival crevicu

SUBMITTER: Bashutski JD 

PROVIDER: S-EPMC4623592 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature